Hospital
ST. Josephs Community Hospital of West Bend INC.
ST. Josephs Community Hospital of West Bend INC. was paid $5.82M by Medicaid between Jan 2018 and Dec 2024, across 178 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoST. JOSEPHS COMMUNITY HOSPITAL OF WEST BEND INC.
WEST BEND, WI 53095
WEST BEND, WI 53095
33aNPI1851336044assigned 06/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.82M
24GClaims294,209
24DCodes billed178
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#22 of 60
Median peer was paid$2.90M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 35,710 | $747K | |
| 2019 | 37,480 | $810K | |
| 2020 | 35,881 | $751K | |
| 2021 | 43,753 | $818K | |
| 2022 | 46,563 | $900K | |
| 2023 | 52,726 | $950K | |
| 2024incomplete | 42,096 | $842K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 17,650 | 15,110 | $961K |
| 96361 | Intravenous infusion, hydration; each additional hour | 14% | 7,458 | 5,241 | $825K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.6% | 11,911 | 10,020 | $557K |
| 80053 | Comprehensive metabolic panel | 5.3% | 12,172 | 9,445 | $311K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 5.0% | 4,535 | 2,809 | $288K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 3,216 | 2,794 | $210K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 3,396 | 3,002 | $200K |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.2% | 9,184 | 7,260 | $185K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 3.0% | 2,515 | 2,052 | $175K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.7% | 3,583 | 2,924 | $159K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.1% | 1,763 | 1,536 | $120K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 18,981 | 14,361 | $110K |
166 more codes
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.8% | 981 | $102K |
| G0378 | Hospital observation service, per hour | 1.7% | 2,913 | $97K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.6% | 939 | $91K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 1,517 | $88K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.3% | 4,326 | $76K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.3% | 5,703 | $75K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.0% | 2,014 | $59K |
| 85610 | <1% | 4,693 | $56K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 690 | $47K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,963 | $46K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 694 | $46K |
| 99285 | Emergency room visit (most serious) | <1% | 1,062 | $45K |
| 84484 | <1% | 6,319 | $45K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,826 | $43K |
| 81025 | <1% | 4,259 | $41K | |
| 87081 | <1% | 2,697 | $34K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 353 | $32K |
| 83880 | <1% | 1,453 | $29K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 483 | $28K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 492 | $28K |
| 87070 | <1% | 2,682 | $26K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 264 | $25K |
| 83735 | <1% | 5,480 | $24K | |
| 83690 | <1% | 4,572 | $24K | |
| 84702 | <1% | 1,653 | $23K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,277 | $23K |
| 80143 | <1% | 1,420 | $19K | |
| 82962 | <1% | 3,385 | $19K | |
| 87077 | <1% | 2,407 | $18K | |
| 81001 | <1% | 5,677 | $18K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 343 | $16K |
| 82077 | <1% | 1,624 | $16K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,193 | $16K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 863 | $16K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 420 | $15K |
| 85027 | <1% | 3,155 | $15K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 777 | $15K |
| 80179 | <1% | 1,383 | $15K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 351 | $13K |
| 87186 | <1% | 2,159 | $13K | |
| 80076 | <1% | 1,982 | $13K | |
| 82728 | <1% | 1,094 | $12K | |
| 82607 | <1% | 832 | $11K | |
| 83605 | <1% | 1,421 | $11K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 314 | $10K |
| 87205 | <1% | 2,698 | $10K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 276 | $10K |
| 85379 | <1% | 1,292 | $10K | |
| 76830 | Ultrasound, transvaginal | <1% | 261 | $9K |
| 84439 | <1% | 1,198 | $9K | |
| 96367 | <1% | 162 | $9K | |
| 81003 | <1% | 1,859 | $8K | |
| 87400 | <1% | 196 | $8K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 300 | $8K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 308 | $6K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,384 | $5K |
| 87040 | <1% | 779 | $5K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 92 | $5K |
| 82805 | <1% | 248 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 105 | $4K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,076 | $4K |
| 87210 | <1% | 721 | $4K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 57 | $4K |
| 80050 | General health panel | <1% | 190 | $4K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,745 | $3K |
| 87147 | <1% | 670 | $3K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 62 | $3K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,676 | $3K |
| 84100 | <1% | 840 | $3K | |
| 76642 | <1% | 56 | $2K | |
| 76801 | <1% | 52 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 80 | $2K |
| 74018 | <1% | 129 | $2K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,889 | $2K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 43 | $2K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 30 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 117 | $2K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 35 | $2K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 17 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 62 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,995 | $2K |
| 74183 | <1% | 21 | $1K | |
| 80061 | Lipid panel | <1% | 79 | $1K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 80 | $889.64 |
| 86850 | <1% | 173 | $801.73 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 31 | $797.50 |
| 83615 | <1% | 235 | $776.98 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 26 | $740.49 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 26 | $740.49 |
| 84145 | <1% | 45 | $707.07 | |
| 93971 | <1% | 35 | $673.14 | |
| 70498 | <1% | 12 | $659.63 | |
| 82746 | <1% | 56 | $622.73 | |
| 86900 | <1% | 312 | $609.83 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,216 | $546.78 |
| 83970 | <1% | 15 | $545.01 | |
| 95806 | <1% | 89 | $536.70 | |
| 86901 | <1% | 251 | $496.92 | |
| Q3014 | Telehealth originating site facility fee | <1% | 15 | $449.80 |
| 84703 | <1% | 72 | $448.56 | |
| 86140 | <1% | 117 | $433.31 | |
| 73630 | <1% | 58 | $373.33 | |
| 94060 | <1% | 13 | $373.27 | |
| 82565 | <1% | 100 | $367.38 | |
| 85730 | <1% | 97 | $325.30 | |
| 88304 | <1% | 43 | $311.76 | |
| 77066 | Tomosynthesis, mammo | <1% | 26 | $302.61 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,221 | $265.31 |
| 90715 | <1% | 49 | $253.56 | |
| 87899 | <1% | 13 | $251.31 | |
| 87106 | <1% | 30 | $238.40 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12 | $236.82 |
| 82570 | <1% | 50 | $234.64 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,134 | $179.91 |
| 77061 | <1% | 28 | $175.24 | |
| 84550 | <1% | 58 | $174.73 | |
| 0352U | <1% | 62 | $161.00 | |
| 73130 | <1% | 72 | $160.06 | |
| 71250 | <1% | 13 | $156.47 | |
| 72131 | <1% | 21 | $154.52 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,911 | $134.09 |
| 83540 | <1% | 26 | $133.81 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12 | $119.92 |
| 82550 | <1% | 27 | $116.35 | |
| 96376 | <1% | 2,833 | $113.61 | |
| 73560 | <1% | 122 | $99.18 | |
| 36416 | <1% | 3,078 | $94.59 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12 | $90.63 |
| 83550 | <1% | 13 | $86.69 | |
| 73110 | <1% | 31 | $76.45 | |
| 85652 | <1% | 47 | $74.44 | |
| 36591 | <1% | 323 | $72.34 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 957 | $71.09 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 769 | $60.65 |
| 84156 | <1% | 20 | $60.37 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,174 | $51.02 |
| 77062 | <1% | 12 | $46.25 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,492 | $10.94 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,430 | $8.58 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,195 | $7.20 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 313 | $2.82 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 881 | $2.46 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,488 | $2.02 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 855 | $0.83 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,805 | $0.82 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,659 | $0.73 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 181 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 925 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 297 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 318 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 55 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 50 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 35 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 48 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 30 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 671 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 468 | $0.00 |
| 73610 | 0% | 32 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 59 | $0.00 |
| Q9956 | Injection, octafluoropropane microspheres, per ml | 0% | 155 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 19 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 100 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 56 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 15 | $0.00 |
| 73030 | 0% | 15 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialERICSON, ALLEN (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Froedtert Health Neighborhood Hospital, LLC | Oak Creek, WI | $1.16M |
| Froedtert Health Neighborhood Hospital, LLC | New Berlin, WI | $1.10M |
| Froedtert Health Neighborhood Hospital, LLC | Mequon, WI | $540K |
| Froedtert Health Neighborhood Hospital, LLC | Pewaukee, WI | $486K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.